Will AI Kill Us All? Doomsday Clock Expert Compares It to Manhattan Project

Will AI Kill Us All? Doomsday Clock Expert Compares It to Manhattan Project

**The Bulletin of the Atomic Scientists Just Moved the Clock to 85 Seconds to Midnight — And They're Saying the Quiet Part Out Loud About AI**

---

## The Question Nobody Wanted to Ask

Let me tell you about a guy named Daniel Holz. He's a physicist at the University of Chicago. He runs something called the Existential Risk Laboratory. And for years, he's been part of a small group of scientists who decide where to set the hands of the Doomsday Clock — that symbolic measure of how close humanity is to destroying itself.

In January 2026, Holz and his colleagues did something they'd never done before. They moved the clock to **85 seconds to midnight** — the closest it's ever been in the nearly 80-year history of the symbol . And for the first time, artificial intelligence was named as a primary driver of that move.

But here's the thing that makes Holz different from the typical AI doomer. He's not some Silicon Valley executive trying to sell you a book or a product. He's not a venture capitalist betting on regulation. He's a scientist who spent his career studying existential threats — nuclear war, climate change, pandemics.

And when he talks about AI, he doesn't reach for science fiction. He reaches for history.

"The scientists who worked on the Manhattan Project, which built the world's first atomic bombs, used the clock to warn the public and policymakers that the technology would dramatically improve and spread," Holz told the Miami Herald in September 2026 .

"It's an extremely powerful technology, just like the power of the atom was a new, extraordinary, powerful technology," he said. "And it's very important to be prudent when the scientists who are developing it are telling you 'maybe we should take a break?'" 

That's the comparison that should stop you in your tracks. Not because AI is literally a nuclear weapon. But because the people building it are saying the same things the Manhattan Project scientists said in 1945.

*This is too powerful. We don't fully understand it. And maybe we should slow down.*

---

## The 10% Number That Changed the Conversation

For years, AI safety advocates have been warning about existential risk. Most people ignored them. They were dismissed as alarmists, doomers, or worse — people with a financial interest in slowing down competitors.

Then September 8, 2026 happened.

Jacob Coxon, a 27-year-old researcher at Anthropic — one of the leading AI companies — resigned. And he didn't go quietly. He posted on X that Anthropic and OpenAI were **"racing straight to self-improving superintelligence and gambling with our lives"** .

The people building AI, he wrote, "earnestly believe that it could kill us all by the end of the decade" .

That post went **viral**. Over 170 million views. Headlines everywhere. And suddenly, the question that had been confined to niche forums and academic papers was being asked on CNN, in Congress, and at kitchen tables across America .

Then the numbers started coming out.

Evan Hubinger, Anthropic's Alignment Science lead, said there was a **greater than 10% chance** that AI could "kill all humans" within the next decade . Marcus Williams, who works on OpenAI's safety oversight team, put the risk at **70% within three years** without regulation or a slowdown .

Geoffrey Hinton, the Nobel Prize-winning computer scientist often called the "godfather of AI," told the BBC that a **10% chance of AI wiping out humanity within a decade was "not unreasonable"** .

And Daniel Holz? His reaction wasn't horror. It was relief.

"You would think my reaction would be, 'Oh no that's terrible,'" he said. "Instead, my reaction was like 'This is terrific. Finally, we can start having the conversation globally about these risks'" .

---

## Why the Manhattan Project Comparison Matters

To understand why Holz reaches for the Manhattan Project, you have to understand something about the people who built the atomic bomb.

They weren't villains. They were scientists — brilliant, patriotic, terrified of what the Nazis might build first. They worked in secret. They did something unprecedented. And then, when it was done, many of them were horrified by what they'd created.

J. Robert Oppenheimer, the scientific director of the Manhattan Project, famously quoted the Bhagavad Gita after the Trinity test: *"Now I am become Death, the destroyer of worlds."*

Albert Einstein, whose letter to FDR helped launch the project, spent the rest of his life advocating for nuclear disarmament.

And in 1945, a group of Manhattan Project scientists founded the **Bulletin of the Atomic Scientists** — the same organization that now sets the Doomsday Clock. Their goal was simple: to warn humanity about the dangers of the technology they had helped create .

The parallel to AI is striking. The people building the most powerful AI systems are the ones warning about them. They're not outsiders looking in. They're the Oppenheimers and Einsteins of our generation, saying: *We built this. We know what it can do. And we're scared.*

"It's an extremely powerful technology, just like the power of the atom was a new, extraordinary, powerful technology," Holz said. "And it's very important to be prudent when the scientists who are developing it are telling you 'maybe we should take a break?'" 

---

## What the Doomsday Clock Actually Says About AI

The Doomsday Clock isn't a prediction. It's a warning. It's a way of communicating to the public and policymakers that the risks we face are real, urgent, and interconnected.

In its 2026 statement, the Bulletin's Science and Security Board wrote that **"artificial intelligence continues to be a significant and disruptive technology"** and that its risks are growing .

The specific concerns they listed are worth reading carefully, because they're not about robots turning on their creators. They're about something more subtle — and arguably more dangerous.

**AI in military systems.** The Bulletin noted that AI is increasingly applied to **command and control, operational planning, logistics, autonomous systems, and cybersecurity** . While some of these applications are relatively benign, others are deeply concerning. The head of U.S. Strategic Command said that while a human will always make the final decision on nuclear weapons, **it's conceivable that AI will be embedded in decision-support systems used for nuclear weapons** .

Think about that. Even if a human is "in the loop," what does that mean if the human is relying on a black-box system that makes recommendations they don't fully understand? What happens when the AI says "launch" and the human has seconds to decide?

The Bulletin called this **"a serious danger"** .

**AI-driven disinformation.** This is the threat that gets less attention but may be the most insidious. The Bulletin warned that **AI is "supercharging mass disinformation"** and making it harder to address other existential threats .

Maria Ressa, a Nobel Peace Prize laureate who participated in the announcement, put it bluntly: **"We are living through an information Armageddon that's brought about by the technology that rules our lives, from social media to generative AI. None of that tech is anchored in facts. Your chatbot is nothing but a probabilistic machine"** .

The concern isn't just that AI can generate fake news. It's that AI can generate **convincing** fake news at **near-zero cost**, flooding the information ecosystem with content that makes it impossible for people to know what's true. And when people can't agree on basic facts, they can't solve problems — including the problems that could end civilization.

**AI-designed pathogens.** This is the scenario that keeps biosecurity experts up at night. The Bulletin noted that **"some researchers are concerned that AI will be employed in the design of unique new pathogens"** .

Steve Fetter, a member of the Bulletin's Science and Security Board, elaborated: **"One clear risk is the use of AI to design novel pathogens—particularly pathogens that don't exist in nature and for which no countermeasures exist"** .

This isn't science fiction. AI systems are already being used to predict protein structures — a capability that could, in theory, be turned toward designing biological agents. The same tools that could cure diseases could be used to create new ones.

---

## The Skeptics: "This Is Not Science"

Not everyone is buying the doomsday narrative. And the skeptics aren't just random people on the internet. Some of them are among the most powerful people in tech.

**Jensen Huang, CEO of Nvidia** — the company that makes the chips powering most AI systems — has been openly dismissive of the extinction warnings.

"2030 is not going to be the end of the world," he said on a podcast in September 2026. "There is 0% chance that's going to be the end of the world. Scaring people is unnecessary. It is irresponsible" .

Huang went further, suggesting that the doomsday narrative is a **strategic play** by AI companies to avoid regulation.

"Don't let this doomsday narrative cause somebody to relieve them of the laws that currently exist," he said. "Read between the lines. They're actually not asking for more laws. They're asking to be relieved of the laws we do have. And I think that that's a problem" .

That's a serious accusation. Huang is essentially saying that the people warning about AI's dangers are doing it to **avoid accountability** — to convince lawmakers that the technology is so powerful and so dangerous that only its creators can be trusted to manage it.

**President Donald Trump** has also dismissed the fears. When asked by reporters whether he had concerns about AI causing human extinction, his answer was blunt: **"No, I don't have any"** .

His concern, he said, was losing the AI race to China. "I have concerns that if we don't win AI, we're going to be put in a very bad position," he said .

That's the geopolitical argument in a nutshell: **We can't slow down because China won't.** If the U.S. pauses AI development, China will surge ahead. And whoever leads in AI will have an insurmountable advantage.

**Even some AI researchers** are skeptical. Chris Hayduk, a life sciences researcher at OpenAI, wrote that AI **"has been and will continue to be an extremely beneficial technology to humanity"** and that the debate should be about "how many billions of lives it will save" .

And The Atlantic, in a nuanced piece published in September 2026, argued that **"maybe the truth of this AI moment sits somewhere in the middle"** — that both the doomers and the skeptics are partially right, and that the format of the debate (happening on platforms that reward sensationalism) is preventing any hope of shared understanding .

---

## Frequently Asked Questions

**Q: What is the Doomsday Clock?**

A: The Doomsday Clock is a symbolic measure created in 1947 by the Bulletin of the Atomic Scientists — an organization founded by Manhattan Project scientists. It represents how close humanity is to self-annihilation. Midnight represents catastrophe. The clock is currently set at **85 seconds to midnight**, the closest it's ever been .

**Q: Why did the Doomsday Clock move forward in 2026?**

A: The Bulletin cited multiple factors, including nuclear weapons threats, climate change, and **disruptive technologies — particularly artificial intelligence**. The specific AI concerns include military applications, disinformation, and the potential for AI-designed pathogens .

**Q: Who is Daniel Holz?**

A: Daniel Holz is a physicist at the University of Chicago, founding director of the University's Existential Risk Laboratory, and chair of the Science and Security Board of the Bulletin of the Atomic Scientists — the group that sets the Doomsday Clock. He has compared the current AI moment to the Manhattan Project .

**Q: What did Jacob Coxon say?**

A: Jacob Coxon, a former researcher at Anthropic, resigned in September 2026 and posted on X that AI companies were **"racing straight to self-improving superintelligence and gambling with our lives."** He said the people building AI "earnestly believe that it could kill us all by the end of the decade" .

**Q: What is the actual risk of AI killing everyone?**

A: Estimates vary widely. Anthropic's Evan Hubinger said there's a **greater than 10% chance** within a decade . OpenAI's Marcus Williams said **70% within three years** without regulation . Nvidia's Jensen Huang said **0%** . There is no scientific consensus.

**Q: How could AI actually kill us all?**

A: The most commonly cited scenario is through **AI-designed bioweapons** — novel pathogens that don't exist in nature and for which no countermeasures exist . Other scenarios include AI in nuclear command and control systems, and AI-driven disinformation that prevents society from addressing other existential threats .

**Q: What is the Manhattan Project comparison about?**

A: The Manhattan Project was the U.S. program that developed the first atomic bombs during World War II. Many scientists who worked on it later warned about the dangers of nuclear technology. The comparison suggests that **the people building the most powerful AI systems are the ones warning about them** — just like the atomic scientists did .

**Q: What does Jensen Huang say about AI extinction risks?**

A: Huang, CEO of Nvidia, has dismissed the warnings as **"irresponsible"** and accused AI companies of using the doomsday narrative to **avoid regulation**. He said there's a **"0% chance"** AI will end the world by 2030 .

**Q: What is Congress doing about AI safety?**

A: Two bills have been proposed. The **FRONTIER Act** would set a framework for deploying advanced AI models . The **Ban Artificial Superintelligence Act** would pause advanced AI development until safety rules are established . Neither has passed.

**Q: What does the European Union say?**

A: The EU has called for **global rules** on AI safety. The European Commission's tech chief said EU law already requires companies to assess the risk of losing control of AI models, but **"that is not the case globally"** .

**Q: Should I be worried about AI?**

A: This article is not offering personal advice. The honest answer is: **experts disagree**. Some of the people closest to the technology are genuinely terrified. Others — including some of the most powerful people in tech — say the fears are overblown. What's clear is that AI is a powerful, rapidly advancing technology with real risks that deserve serious attention.

---

## Conclusion: The Conversation We Can't Avoid

Here's what I keep coming back to when I think about Daniel Holz and the Doomsday Clock.

The clock was created by scientists who had just built the most destructive weapon in human history. They weren't trying to scare people. They were trying to **warn** them. To say: *This is what we've made. This is what it can do. We need to be careful.*

Eighty years later, the same warning is being issued about AI. And the people issuing it aren't outsiders. They're the ones building the technology.

Jacob Coxon quit his job to sound the alarm. Evan Hubinger, who still works at Anthropic, says there's a 10% chance his own company's products could kill everyone. Geoffrey Hinton, who won a Nobel Prize for his work on neural networks, says the risk is real.

These aren't people with nothing to lose. They're people who have everything to lose — and who are speaking up anyway.

But they're also not the only voices in the room. Jensen Huang says the warnings are a regulatory power play. Donald Trump says the only thing that matters is beating China. And millions of people are using AI every day to write emails, generate images, and automate work — with no apparent catastrophe.

The truth is probably somewhere in the messy middle. AI might not kill us all. But it's clearly a technology with enormous power — power that could be used for great good or great harm. And the people building it are telling us they're not sure which way it will go.

That's the conversation Holz wants us to have. Not a debate about whether AI is good or evil. But a serious, global conversation about **how to manage a technology that could reshape civilization**.

The Doomsday Clock isn't a prediction. It's a warning. And right now, it's saying: **Pay attention. This is real. And we need to talk about it.**

---

## Disclaimer

**This article is for informational and educational purposes only. It does not constitute investment, policy, or personal safety advice. The author has no positions in any AI-related securities mentioned. Information presented here is based on publicly available sources and reported statements as of the publication date. The debate about AI existential risk is ongoing, and expert opinions vary widely. Readers should seek diverse perspectives and consult qualified professionals before making decisions based on the information presented. The author does not have access to non-public information about AI systems or their capabilities.**

Moderna Stock Hits a New High as CEO Says It’s More Than Covid Vaccines

 Moderna Stock Hits a New High as CEO Says It’s More Than Covid Vaccines

**The Biotech Giant Just Reminded Wall Street That It Was Never Just a Pandemic Story — And Investors Are Finally Listening**

---

## The Moment That Changed the Narrative

Let me tell you about a woman named Karen. She’s a portfolio manager at a mid-sized investment firm in Boston. She’s been watching Moderna for years. She remembers the pandemic days when the stock was flying high, and she remembers the crash that followed when the world moved on from Covid.

For most of 2024 and 2025, Karen couldn’t get her colleagues to take Moderna seriously. “It’s a one-trick pony,” they’d say. “Covid is over. What else do they have?”

She’d try to explain about the pipeline. About the mRNA platform. About the cancer vaccine. But nobody wanted to hear it. The stock was dead, and that was that.

Then August 19, 2026 happened. Moderna announced positive Phase 3 data for its personalized cancer vaccine, and the stock **nearly tripled in a single day**. Karen’s phone started ringing. Suddenly, everyone wanted to talk about Moderna.

And then this week, something even more interesting happened. On Wednesday, September 23, Moderna CEO Stéphane Bancel took the stage at Bernstein’s annual healthcare conference and said something that cut to the heart of the debate.

“Moderna has never been a Covid vaccine company,” he said. “We’re an mRNA platform company”.

The stock hit a **52-week high of $192.31** that day. It closed the week at **$194.82**, up nearly **7%** on Thursday alone. Year-to-date, the stock is up more than **500%**.

Karen was right. And now the rest of the market is playing catch-up.

---

## The Numbers: A Stock on Fire

Let’s get the raw data on the table, because the magnitude of this move is genuinely historic.

**The Price Action:**

Moderna shares closed Thursday, September 24, at **$194.82**, up **6.98%** for the day. The stock hit an intraday high of **$195.71** — a new 52-week high. The previous close was $182.11.

But the daily move is just the tip of the iceberg.

**The Longer-Term Picture:**

- **1-week return:** +25%

- **1-month return:** +31%

- **3-month return:** +205%

- **Year-to-date:** +517%

- **1-year return:** +606%

Over the past 52 weeks, Moderna has traded between a low of **$22.28** and a high of **$195.71**. That’s a range of nearly **800%**.

The stock now carries a **market capitalization of approximately $72.7 billion**.

**The Volume:**

Trading volume has been elevated, with **16.4 million shares** changing hands on Thursday alone — close to the three-month average of 16.7 million. On Wednesday, volume hit **17.7 million**, and on Monday, it was **21 million**. Investors are paying attention.

---

## Why This Is Happening: The Cancer Vaccine Story

To understand why Moderna is surging, you have to understand what happened in August.

On August 19, 2026, Moderna and its partner Merck announced that their personalized cancer vaccine, **intismeran autogene**, had achieved a major breakthrough in a Phase 3 trial. The study evaluated the vaccine in combination with Merck’s Keytruda as an adjuvant treatment for patients with resected melanoma — skin cancer that had been surgically removed but carried a high risk of recurrence.

The results showed that the combination **prevented cancer from returning more effectively than Keytruda alone**. The trial met both its primary endpoint and a secondary endpoint of distant metastasis-free survival at the first interim analysis.

This wasn’t a small trial. It involved approximately **1,100 patients** in a rigorously controlled, blinded study.

The stock reaction was explosive. Moderna shares **nearly tripled in a single session** — a move that made headlines across Wall Street.

“The Phase 3 results marked a major success for the field of personalized cancer vaccines,” noted Leerink Partners analyst Lili Nsongo, who added that previous failures in the field “paint a complex picture for mRNA cancer vaccines”.

What makes intismeran different is its **personalization**. The vaccine is engineered to flag dozens of mutations unique to each patient’s tumor. It’s not a one-size-fits-all treatment. It’s a custom-built therapy designed for each individual’s cancer.

“Moderna owns the proprietary work involved in selecting the 34 mutations included in each individualized cancer vaccine,” Bancel explained at the Bernstein conference. External partners provide DNA sequencing data, but Moderna handles the downstream analysis and selection process.

---

## Beyond Covid: The Platform Story

But here’s the thing that Bancel wants investors to understand: Covid was never the point. It was an opportunity. A validation. A proof of concept.

“Moderna has been an mRNA platform company since its founding,” Bancel said. The Covid vaccine was “an unplanned but necessary response to the pandemic rather than the company’s long-term strategy”.

The company now has **five approved products** and two product launches planned for this year. That’s up from zero in 2020.

**The Respiratory Vaccine Business**

Moderna’s commercial portfolio includes:

- **Spikevax** (Covid-19 vaccine), approved in 40 countries

- **mNEXSPIKE** (next-generation Covid vaccine), approved in the U.S. and Canada

- **mRESVIA** (RSV vaccine), approved in 40 countries

- **mRNA-1010** (seasonal flu vaccine), submissions completed in major markets

- **mRNA-1083** (flu + Covid combination vaccine), under review in Europe and Canada

The company expects growth from long-term partnerships in the UK, Canada, and Australia, and is targeting entry into the flu vaccine market in 2027. By 2028, Moderna anticipates a first-to-market flu/Covid combination vaccine and a potential norovirus vaccine, expanding its seasonal franchise to as many as **six approved products**.

**The Oncology Pipeline**

Intismeran is just the beginning.

Moderna has **eight Phase 2 and Phase 3 clinical trials underway** for the cancer vaccine across multiple tumor types, including melanoma, non-small cell lung cancer, bladder cancer, and renal cell carcinoma.

Chief Development Officer David Berman outlined the breadth of the program at the Bernstein conference. There are ongoing studies in:

- Lung cancer (three Phase 3 trials)

- Renal cell carcinoma

- Bladder cancer

- Pancreatic cancer

- Gastric cancer

The company is also studying intismeran in earlier stages of disease, including a Phase 3 trial in stage 1 lung cancer and a randomized Phase 2 trial in non-muscle-invasive bladder cancer.

Berman noted that Moderna’s view is that the treatment **may be active without a PD-1 inhibitor** — potentially creating opportunities in settings where checkpoint inhibitors are not commonly used.

**The Rare Disease Pipeline**

Beyond oncology, Moderna is advancing programs in rare genetic diseases. Bancel said the company expects **pivotal data for propionic acidemia by year-end**. He described the program as the first of what could become a broader liver-focused rare-disease franchise, using mRNA to direct the liver to produce missing or deficient proteins.

Moderna has published work involving more than **12 rare genetic liver-disease models** and intends to advance additional programs using the same delivery approach and manufacturing infrastructure.

---

## The Next Catalyst: ESMO Presentations

If you’re trying to understand what could drive the stock from here, mark your calendar for late October.

Moderna announced Monday that **three abstracts on intismeran autogene** have been accepted for presentation at the **European Society for Medical Oncology (ESMO) Congress 2026**, to be held October 23-27 in Madrid, Spain.

This is one of the largest oncology conferences in the world. And the presentations will provide the first full, detailed look at the data that caused the stock to nearly triple in August.

**The three presentations:**

1. **The flagship presentation:** Full Phase 3 results for intismeran autogene plus Keytruda as adjuvant treatment for resected melanoma. This is the data that started everything.

2. **Pancreatic cancer:** Early-stage trial results for the vaccine following Folfirinox, an aggressive chemotherapy regimen, in cancer confined to the small ducts in the pancreas.

3. **Lung cancer:** Phase 3 results showing the efficacy of intismeran autogene alongside immunotherapy in patients with early-stage non-small cell lung cancer.

“The highest-profile presentation will showcase the results of a Phase 3 trial evaluating a combination of intismeran autogene and Merck’s Keytruda,” Barron’s noted. “An early look at the data in August showed the combined treatment prevented cancer from returning more effectively than Keytruda alone”.

Investors should expect volatility around the event. The August data release caused a massive move. The full data could either confirm the enthusiasm or raise questions.

---

## The Partnership with Merck: A Strategic Alliance

Intismeran isn’t a solo effort. It’s being developed in partnership with **Merck**, one of the world’s largest pharmaceutical companies.

The collaboration dates back years. Merck paid **$200 million upfront** to kick off the project and another **$250 million in 2022**. Under the current agreement, the companies **share costs equally** — including commercial, clinical, manufacturing, and capital expenditures — with remaining profit **split evenly**.

For Merck, the partnership is strategic. Keytruda, its blockbuster immunotherapy, has been the world’s best-selling drug for roughly three years. But it faces **loss of exclusivity in 2028**. Merck has been scrambling to expand its pipeline and secure new indications for Keytruda.

Intismeran could be the answer. If approved, it would shift Keytruda “from a drug facing a patent cliff into the cornerstone of a personalized platform”.

For Moderna, the partnership provides validation, resources, and commercial reach. Merck’s oncology salesforce is one of the most experienced in the industry.

---

## The Manufacturing Challenge: Scaling Personalization

Here’s the thing about personalized cancer vaccines: they’re incredibly difficult to manufacture at scale.

Unlike traditional vaccines, which are produced in massive batches, intismeran is **custom-made for each patient**. The process involves:

1. Collecting a patient’s tumor sample

2. Sequencing the DNA to identify unique mutations

3. Selecting the 34 most promising targets

4. Manufacturing a custom mRNA vaccine

5. Shipping it back to the hospital for administration

This is complex. It’s time-sensitive. And it requires coordination between Moderna, Merck, hospitals, and patients.

Bancel acknowledged the challenge at the Bernstein conference. He said the **principal bottleneck may be hospital operations** rather than manufacturing — particularly the ability to rapidly obtain biopsies and related patient information.

“Moderna and Merck are establishing teams to support hospitals and standardize those processes,” Bancel said. The companies have built a **digital platform** to track operational steps while maintaining patient privacy.

Moderna has also built a **purpose-built facility in Marlborough, Massachusetts**, specifically for intismeran manufacturing. The site is “designed for speed and scalability with advanced automation and robotics,” and began clinical batch supply in September 2025.

Bancel described intismeran manufacturing as “a synthetic, cell-free liquid process that can be scaled through smaller equipment footprints and faster cycle times”.

---

## Frequently Asked Questions

**Q: What caused Moderna stock to hit a new high this week?**

A: CEO Stéphane Bancel told investors at the Bernstein healthcare conference that Moderna is “an mRNA platform company,” not just a Covid vaccine maker. He highlighted the company’s expansion into oncology and rare diseases, including its personalized cancer vaccine, intismeran autogene. The stock hit a 52-week high of $192.31 on Wednesday and closed at $194.82 on Thursday.

**Q: What is intismeran autogene?**

A: It’s Moderna’s personalized cancer vaccine, developed in partnership with Merck. It’s engineered to flag dozens of mutations unique to each patient’s tumor. The vaccine is custom-made for each individual based on their cancer’s genetic profile.

**Q: How did the cancer vaccine perform in clinical trials?**

A: In August 2026, Moderna and Merck announced that a Phase 3 trial showed the vaccine, combined with Merck’s Keytruda, prevented melanoma from returning more effectively than Keytruda alone. The trial involved approximately 1,100 patients. The stock nearly tripled on the news.

**Q: What’s next for Moderna’s cancer vaccine?**

A: Moderna will present full data at the European Society for Medical Oncology (ESMO) Congress in late October 2026. The company is also planning to file for regulatory approval. Beyond melanoma, the vaccine is being studied in lung cancer, bladder cancer, pancreatic cancer, and other tumor types.

**Q: Is Moderna still a Covid vaccine company?**

A: Yes and no. Covid vaccines remain a significant part of Moderna’s business — the company has five approved products, including Covid and RSV vaccines. But CEO Bancel says the company “has never been” just a Covid vaccine company. It’s an mRNA platform company using its technology across infectious diseases, oncology, rare diseases, and autoimmune conditions.

**Q: What does the analyst community think about Moderna stock?**

A: Analysts are divided. According to 23 analysts polled by S&P Global, the consensus rating is **Hold**, with an average price target of **$119.56** — implying about **38% downside** from current levels. However, several firms have raised their targets following the cancer vaccine data, with some now in the $150-$170 range.

**Q: Why is there such a big gap between the stock price and analyst targets?**

A: The stock has rallied dramatically — up over 500% year-to-date — on the strength of the cancer vaccine data. Many analysts have been slow to update their models to reflect the full potential of intismeran. Some remain skeptical that the market opportunity justifies the current valuation. Others are waiting for more data before adjusting their forecasts.

**Q: What are the risks for Moderna investors?**

A: Key risks include: (1) **Execution risk** on the personalized cancer vaccine — manufacturing and commercializing a custom therapy at scale is extremely difficult. (2) **Tumor type variability** — the melanoma data was strong, but the vaccine may not work as well in other cancers. (3) **Competition** — other companies are pursuing mRNA cancer vaccines, though BioNTech recently scrapped a trial for its own candidate. (4) **Valuation** — the stock has already priced in a lot of optimism.

**Q: What is Moderna’s financial position?**

A: Moderna reported a net loss of **$1.3 billion** in Q1 2026. The company has cash and investments of approximately **$7.5 billion** (as of March 2026) and recently raised **$2.6 billion through convertible notes**. Revenue for 2026 is projected to grow up to 10% from 2025 levels.

**Q: What other products does Moderna have in development?**

A: Beyond the cancer vaccine, Moderna is developing:

- **mRNA-1083**, a flu + Covid combination vaccine (under review in Europe and Canada)

- **mRNA-1403**, a norovirus vaccine (Phase 3 ongoing)

- **Propionic acidemia treatment**, with pivotal data expected by year-end

- **Multiple rare disease programs** targeting liver diseases

- **In vivo CAR-T** and other autoimmune disease programs

**Q: When is Moderna’s next earnings report?**

A: Moderna is expected to report Q3 2026 earnings on **Thursday, November 5, 2026**.

**Q: Should I buy Moderna stock now?**

A: This article is not financial advice. Whether to buy Moderna depends on your individual financial situation, risk tolerance, and investment thesis. The stock has already rallied dramatically, and analysts are divided on whether the current valuation is justified. Do your own research and consider consulting a financial advisor.

---

## Conclusion: A Company Transformed

Here’s what I keep coming back to when I think about Karen, the portfolio manager in Boston.

She spent years trying to convince people that Moderna was more than Covid. She had the science. She had the pipeline. She had the vision. But nobody wanted to listen.

Now they’re listening.

The stock is up **over 500% this year**. It hit a new 52-week high this week. And the catalyst that drove the rally — a personalized cancer vaccine that could change how we treat cancer — is just beginning to show what it can do.

CEO Stéphane Bancel’s message at the Bernstein conference was simple: **Moderna was never a Covid company**. It’s an mRNA platform company. And the platform is now delivering results across multiple therapeutic areas.

The next few months will be critical. The ESMO presentations in late October will provide the full data on intismeran. The company is preparing for regulatory filings. And pivotal data for its rare disease program is expected by year-end.

For investors, the question is whether the current valuation reflects reality or hype. Analysts are divided, with some seeing significant downside and others believing the rally is just getting started.

But for Karen, the debate is settled. She saw the science before the market did. And now the market is catching up.

Moderna isn’t just a Covid vaccine company anymore. It’s a cancer vaccine company. A rare disease company. A platform company.

And the market is finally starting to believe it.

---

## Disclaimer

**This article is for informational and educational purposes only. It does not constitute investment, financial, or medical advice. The author has no position in Moderna (MRNA), Merck (MRK), or any related securities. Information presented here is based on publicly available sources and reported figures as of the publication date. Clinical trial results are not guarantees of future performance or regulatory approval. The stock market involves risk, including the potential loss of principal. Past performance does not guarantee future results. Always consult with a qualified financial advisor before making any investment decisions.**

Costco Wins $184M in Tariff Refunds, with More Expected

 Costco Wins $184M in Tariff Refunds, with More Expected

**The Warehouse Giant Just Got a Massive Check from the Government — And It's Giving Most of It Back to You**

---

## The Check That Came in the Mail

Let me tell you about a guy named Dave. He's a Costco member in suburban Phoenix. Been shopping there for fifteen years. Executive membership. Buys everything from bulk paper towels to rotisserie chickens to his kid's school snacks.

Dave doesn't follow earnings calls. He doesn't read SEC filings. He just knows that when he walks into Costco, he gets a good deal.

But last month, Dave noticed something. The price of his favorite Kirkland Signature Colombian coffee dropped. The walnuts he buys for his morning oatmeal got cheaper. Even the paper towels — the ones he buys in those giant packs — seemed to cost a little less.

He didn't think much of it. Just assumed Costco was running a sale.

What Dave didn't know was that he was benefiting from one of the most interesting corporate decisions of the year. Costco had just received a **$184 million refund** from the U.S. government for tariffs it had paid. And instead of pocketing the money, the company decided to give most of it back to members like Dave.

That's not just good business. That's a statement of values. And it's a story every American shopper should understand.

---

## The Numbers: What Costco Actually Received

Let's get the facts straight, because the details matter.

On September 24, 2026, Costco reported its fiscal fourth-quarter and full-year earnings for the period ending August 30 . Buried in those numbers was a line item that made investors and shoppers take notice: **$184 million in tariff refunds** received during the quarter .

That money broke down into two pieces: **$174 million in principal refunds** and **$10 million in interest** . The refunds stemmed from tariffs collected under the International Emergency Economic Powers Act (IEEPA) — tariffs that the Supreme Court ruled unlawful in February 2026 .

Costco's Chief Financial Officer, Gary Millerchip, told analysts on the earnings call that this initial payment represented **"a little more than one-third"** of the total refunds the company expects to receive . And here's the key detail: Costco had **already received a similar amount** in the first quarter of fiscal 2027 .

Do the math. If $184 million is one-third of the total, Costco is looking at roughly **$500 million or more** in refunds when all is said and done .

That's a lot of money. And it raises a question every Costco member should be asking: *What is the company going to do with it?*

---

## The Decision: Giving It Back

Here's where the story gets interesting.

Costco could have kept the refunds. It could have booked them as pure profit. It could have distributed them to shareholders through dividends or buybacks.

Instead, the company did something that says everything about its business model.

**Costco reinvested the majority of the refunds into lower prices for members** .

Chief Executive Officer Ron Vachris explained the logic during the earnings call. The company targeted items **"that would have the most impact for members"** — everyday products in produce, meat, and beverages, plus non-food items like home furnishings and hardware that had been hit hardest by the tariffs .

Millerchip put it simply: **"Our goal is to be the first to lower prices where we see opportunities to do so"** . He cited specific examples — reductions on Kirkland Signature walnuts, Colombian whole bean coffee, dry facial towels, and coarse black pepper .

This wasn't a marketing gimmick. It wasn't a temporary sale. It was a deliberate decision to pass tariff refunds through to the people who ultimately paid the tariffs in the first place.

---

## Why This Matters: The Economics of Tariffs

To understand why Costco's decision is so significant, you need to understand something about tariffs that most people don't realize.

**Tariffs are paid by American importers, not foreign companies.**

When the U.S. government imposes a tariff on imported goods, the importer of record — in this case, companies like Costco — pays the duty to U.S. Customs and Border Protection . The foreign manufacturer doesn't write a check. The American company does.

And here's the part that matters most: **those costs get passed on to consumers**.

Economists have studied this extensively. The Federal Reserve Bank of New York found that when tariffs increase the cost of imported goods, retailers pass a significant portion of those costs through to customers in the form of higher prices .

So when Costco paid tariffs on imported coffee, walnuts, furniture, and hardware, the cost didn't disappear. It showed up in the prices members paid at the warehouse.

When the Supreme Court ruled those tariffs unlawful, it created a pathway for importers to get their money back . Costco sued. It got in line. And now it's receiving refunds.

But here's the ethical question: *Who should get that money?*

Costco's answer was clear. The members who paid the higher prices should benefit. Not the shareholders. Not the executives. The members.

---

## The Lawsuit That Changed Everything

There's another layer to this story that makes it even more compelling — and more complicated.

Costco isn't just giving refunds back to members out of the goodness of its heart. The company is facing a **proposed class-action lawsuit** filed earlier this year .

The lawsuit alleges that Costco:

1. Raised prices due to tariffs

2. Represented that prices remained competitive

3. Failed to disclose that it intended to seek tariff refunds

4. Retained tariff refunds despite having passed the costs to customers 

The plaintiffs argue that Costco's retention of tariff refunds — after having shifted those costs to consumers — constitutes an unfair or deceptive act .

Costco hasn't commented publicly on the specifics of the litigation. But CEO Ron Vachris acknowledged during the earnings call that the company's decision to reinvest refunds into member value is connected to the legal proceedings. He said the specific amount and timing of future refund distributions will depend on **"how the refund litigation against the company develops"** .

So is Costco giving the money back because it's the right thing to do? Or because it's legally required to?

The honest answer is: probably both.

But here's what matters for members: **the money is coming back either way**. Whether motivated by ethics or legal pressure, Costco is passing tariff refunds through to the people who paid them.

---

## The Human Impact: What This Means for Your Wallet

Let's bring this back to Dave, the Costco member in Phoenix.

He noticed his coffee got cheaper. He noticed the walnuts cost less. He might not know why, but he's benefiting.

Millions of Costco members are in the same position. They're seeing lower prices on everyday items. They're getting more value for their membership fee. They're experiencing the tangible results of a corporate decision to prioritize customers over short-term profits.

And the scale of the refunds means this isn't over.

Costco has already received roughly **$370 million** in refunds — $184 million in Q4 plus a similar amount in Q1 of fiscal 2027 . If the total is indeed around $500 million or more, there's still another **$130 million or more** coming .

That means more price reductions. More value passed back to members. More reasons for Dave — and millions of others — to keep shopping at Costco.

---

## The Financial Picture: Strong Results Beyond the Refunds

It would be a mistake to think Costco's quarter was only about tariff refunds. The company delivered genuinely strong results across the board.

**Net sales for the quarter increased 11.2% to $93.9 billion**, up from $84.4 billion last year . For the full fiscal year, net sales hit **$297.2 billion**, a 10.1% increase .

**Net income for the quarter was $2.998 billion, or $6.75 per diluted share** — up from $2.610 billion, or $5.87 per share, last year . The tariff refunds contributed **$0.15 per diluted share** to that figure .

Strip out the one-time refund benefit, and Costco still grew earnings by **12.3%** . That's not a company relying on a government check. That's a company executing its core business exceptionally well.

**Membership fee income rose 7.3% to $1.849 billion** . Total paid members reached **84.1 million**, and paid executive members hit **42.3 million**, up 9.4% . Renewal rates improved to **92.3% in the U.S. and Canada** and **89.8% worldwide** .

**Digital sales grew nearly 20%** on a comparable basis, and Costco's partnership with Uber Eats for same-day delivery expanded from 17 states to nationwide .

And here's a demographic data point that's worth noting: **Costco members under 40 have increased nearly 60% since the pandemic** and now represent more than a quarter of the membership base . The company is attracting younger shoppers — a critical indicator for long-term health.

---

## Frequently Asked Questions

**Q: What exactly did Costco receive?**

A: Costco received **$184 million in tariff refunds** during its fiscal fourth quarter: $174 million in principal refunds and $10 million in interest . This represents a little more than one-third of the total refunds the company expects .

**Q: Why did Costco get these refunds?**

A: The refunds stem from tariffs imposed under the International Emergency Economic Powers Act (IEEPA). In February 2026, the Supreme Court ruled that the president lacked authority to impose tariffs under IEEPA, making the tariffs unlawful and creating a pathway for importers to seek refunds .

**Q: What is Costco doing with the money?**

A: Costco is **reinvesting the majority of the refunds into lower prices for members** . The company has reduced prices on everyday items in produce, meat, and beverages, as well as non-food items like home furnishings and hardware .

**Q: How much more is Costco expecting?**

A: The $184 million represents roughly one-third of the total. Costco has already received a similar amount in Q1 fiscal 2027. The total is estimated at **$500 million or more** .

**Q: Why is Costco giving the money back instead of keeping it?**

A: Two reasons. First, Costco's business model is built on delivering value to members — the company operates on thin merchandise margins and makes most of its profit from membership fees. Second, Costco faces a class-action lawsuit alleging it improperly retained tariff refunds after passing costs to consumers .

**Q: Is the class-action lawsuit connected to the refunds?**

A: Yes. The lawsuit alleges that Costco raised prices due to tariffs, then failed to disclose its intent to seek refunds, and retained the refunds despite having passed costs to customers . CEO Ron Vachris acknowledged that the refund distribution is connected to how the litigation develops .

**Q: How much will individual members get back?**

A: This isn't a direct cash payout. The refunds are being passed through **lower prices** on specific items. If the total refunds reach $500 million and are spread across 84.1 million paid members, that's roughly **$6 per member** — but delivered through price reductions rather than checks .

**Q: Which products have seen price reductions?**

A: CFO Gary Millerchip cited specific examples: **Kirkland Signature walnuts, Colombian whole bean coffee, dry facial towels, and coarse black pepper** . Reductions have also been applied to produce, meat, beverages, home furnishings, and hardware .

**Q: How did Costco's overall earnings look?**

A: Strong. Net sales rose **11.2%** to $93.9 billion for the quarter. Net income was **$2.998 billion, or $6.75 per share** — including the $0.15 per-share refund benefit. Excluding the refund, earnings still grew **12.3%** .

**Q: What about membership growth?**

A: Total paid members reached **84.1 million**, up 3.8%. Executive members hit **42.3 million**, up 9.4%. Renewal rates improved in both the U.S./Canada and worldwide .

**Q: Are other retailers doing the same thing?**

A: Walmart, Kroger, and Albertsons are also lowering prices using tariff refunds to fund investments in competitive pricing, according to reports . Costco isn't alone, but its commitment to passing refunds through to members has been particularly notable.

**Q: What should members watch for next?**

A: More price reductions as additional refunds arrive. Costco has said it will continue reinvesting the majority of refunds into member value . Watch for lower prices on items that were most affected by tariffs — particularly non-food categories like furniture and hardware.

---

## Conclusion: The Costco Difference

Here's what I keep coming back to when I think about Dave and his cheaper coffee.

Costco could have kept that $184 million. It could have booked it as profit. It could have boosted its earnings per share and made Wall Street happy.

Instead, it gave the money back.

Yes, there's a lawsuit. Yes, there's legal pressure. Yes, the company is protecting itself. But there's also something else happening here — something that explains why Costco has built one of the most loyal customer bases in American retail.

**The membership model creates alignment.**

Costco doesn't make its money on merchandise markups. It makes its money on membership fees. The company's entire business model depends on members renewing year after year. And members renew when they feel like they're getting value.

So when Costco gets a windfall from tariff refunds, the smart play isn't to pocket the money. It's to pass it back to members, reinforce the value proposition, and keep those renewals coming.

That's not charity. That's strategy. But it's the kind of strategy that benefits everyone — the company, the shareholders, and most importantly, the members who walk through those warehouse doors every week.

Dave doesn't know about the Supreme Court ruling. He doesn't know about the class-action lawsuit. He doesn't know about the earnings call or the CFO's comments.

He just knows his coffee costs less. And that's enough to keep him coming back.

---

## Disclaimer

**This article is for informational and educational purposes only. It does not constitute investment, financial, or legal advice. The author has no position in Costco Wholesale Corporation (COST) or any related securities. Information presented here is based on publicly available sources and reported figures as of the publication date. The class-action lawsuit referenced is ongoing, and outcomes are uncertain. Anecdotal accounts are illustrative and do not represent specific individuals. Investing involves risk, including the potential loss of principal. Always consult with a qualified financial advisor before making any investment decisions.**

U.S. Treasury Yields Are Ending the Week Sharply Higher

 

U.S. Treasury Yields Are Ending the Week Sharply Higher

**The 30-Year Just Hit a 22-Year High. The 10-Year Touched 5.22%. And American Families Are About to Feel It in Ways They Didn't Expect.**

---

## The Week That Bond Investors Won't Forget

Let me tell you about a woman named Patricia. She's a retired schoolteacher in her late sixties, living in a modest house in suburban Sacramento. She's got a pension, some savings, and a portfolio of bonds her late husband set up years ago to generate steady income.

For most of her retirement, those bonds did exactly what they were supposed to do. They paid predictable interest. They didn't keep her up at night.

But this week? Patricia watched her bond portfolio lose value day after day. She doesn't fully understand yields and prices and basis points. But she understands the bottom line: her nest egg is shrinking, and nobody seems able to explain why.

"I called my broker twice," she told me. "He said something about the 30-year hitting a high. I said, 'A high of what? Is that good or bad?'"

It's bad. If you own bonds, or bond funds, or a target-date retirement fund with a bond allocation, this week hurt. And the pain isn't over.

---

## The Numbers: A Historic Selloff in Bonds

Let's get the data on the table, because this week's move in Treasuries was genuinely historic.

**The 30-year Treasury yield** climbed to **5.48%** during the week — its highest level since **2004**. That's a **22-year high**. 

**The 10-year Treasury yield** — the benchmark that influences mortgage rates, corporate borrowing costs, and just about everything else in finance — touched **5.225%** intraday, its highest since **July 2007**. 

**The 2-year Treasury yield**, which tracks what the market thinks the Federal Reserve will do with interest rates, climbed to **4.90%**, near a two-year high. 

The yield curve **steepened dramatically**, meaning long-term yields rose much more than short-term yields. The spread between the 10-year and 2-year hit its widest level since mid-month. 

This wasn't a one-day blip. The 10-year yield rose for a **sixth consecutive week** — its longest weekly losing streak since **November 2024**. 

And the selloff wasn't just in the U.S. Bond markets worldwide came under pressure. **Japan's 10-year government bond yield** hit its highest level since **1996**. **Germany's 10-year Bund** touched its highest in **17 years**. 

This is a global repricing of risk. And it's happening fast.

---

## Why This Is Happening: A Perfect Storm

To understand why Treasury yields are surging, you have to understand three forces that are all pulling in the same direction.

### Force #1: The Fed Is Done Cutting — And Starting to Hike

In mid-September, the Federal Reserve did something it hadn't done since **July 2023**: it **raised** interest rates. The federal funds rate went up by a quarter-point to **3.75% to 4.00%**. 

But the rate hike itself wasn't the shock. The shock was what the Fed signaled about the future.

The Fed's "dot plot" — a chart showing where policymakers expect rates to go — showed that most officials expect **at least one more hike this year**. The median projection for the end of 2026 jumped to **4.1%**, up from 3.9% in June. 

Fed Chair Kevin Warsh, who took over earlier this year, made it clear: the Fed is serious about fighting inflation, and it's not going to be pressured by politics.

"Reaching price stability eventually benefits workers," Warsh said at his press conference. "The economy is strong enough to handle this tightening." 

Traders got the message. By Friday, fed funds futures put the odds of **another rate hike in October at about 71%** — up from roughly even odds earlier in the week. Markets are now pricing in **close to four more quarter-point hikes** before this cycle ends. 

### Force #2: Oil Prices Are Surging — Again

If the Fed were the only problem, the bond selloff might be manageable. But it's not.

Oil prices are climbing, driven by the ongoing conflict with Iran and attacks on Saudi oil infrastructure. This week, **Houthi rebels attacked the Yanbu region near Saudi Arabia's border**, sending **WTI crude up nearly 5%** at one point. 

**Brent crude** settled around **$102 per barrel**, with intraday spikes higher. 

Here's why this matters for bonds: **oil prices feed directly into inflation**. When energy costs rise, businesses pay more to operate. Those costs get passed to consumers. Inflation expectations rise. And when inflation expectations rise, bond investors demand higher yields to compensate for the risk that their returns will be eroded.

The Fed's job gets harder, not easier, when oil is surging. And the market knows it.

### Force #3: The Economy Just Won't Slow Down

Perhaps the most surprising data point this week came from the **S&P Global U.S. Composite PMI**, a measure of business activity.

The September preliminary reading came in at **58.4** — up from 56 in August. That's the **highest level since July 2021**. Economists expected it to decline. Instead, it accelerated. 

The **new orders index** — a leading indicator of future activity — jumped to its highest since March 2022. And the **prices paid index** surged to **66.4**, the highest since **October 2022**, signaling that businesses are facing and passing on higher costs. 

Chris Williamson, chief business economist at S&P Global, put it bluntly: **"U.S. business activity continues to boom."** 

A booming economy sounds like good news. And in many ways, it is. But for bond markets, it's complicated. Strong growth means the Fed has less reason to cut rates. Strong growth means inflation pressure persists. Strong growth means the "risk-free rate" — the yield investors demand for lending money to the government — should be higher.

**Zachary Griffiths, head of investment grade strategy at CreditSights**, explained it well: **"You're seeing a repricing of several things — U.S. economic growth has remained resilient, and that's a more positive reason why you would find yourself in a higher risk-free rate environment."** 

---

## The Human Cost: What This Means for Real Americans

Let me bring this back to Patricia, the retired teacher in Sacramento.

She doesn't trade bonds. She doesn't follow the Fed. She just wants her retirement to be stable.

But here's what's happening to her, and to millions of Americans like her:

**If You Own Bonds or Bond Funds**

Bond prices fall when yields rise. That's the iron law of fixed income. If you own individual bonds and hold them to maturity, you'll get your principal back and you'll collect the interest payments. But if you own **bond funds** — which most retirement accounts do — the value of your holdings has declined this week.

The damage varies depending on what you own. Long-term Treasury funds have been hit hardest. Short-term bond funds have held up better. But almost everyone with a diversified portfolio has felt some pain.

**If You're Trying to Buy a Home**

Mortgage rates follow the 10-year Treasury yield. And the 10-year just hit 5.22%. **The 30-year fixed mortgage rate is now around 7%** — a level that has frozen the housing market. 

For buyers, every basis point increase in mortgage rates means higher monthly payments. A $400,000 mortgage at 6.5% costs about $2,528 per month. At 7%, it costs $2,661. That's **$133 more every month** — nearly **$1,600 a year** — for the same house.

And rates could go higher if Treasury yields keep climbing.

**If You're a Business Owner**

Corporate borrowing costs are tied to Treasury yields. When yields rise, it costs more for businesses to expand, invest, or refinance debt. Small businesses with floating-rate loans feel the pain immediately. Larger companies face higher costs when they issue new bonds.

**If You're a Saver**

Here's the one silver lining: **savings accounts, CDs, and money market funds are paying more**. If you have cash in the bank, you're finally earning meaningful interest. High-yield savings accounts are offering rates above 4%. Treasury bills are yielding even more.

For retirees like Patricia who have cash on the sidelines, this is a small consolation. For younger Americans building emergency funds, it's a genuine opportunity.

---

## The "6% Threshold": Why It Matters

Investors are now eyeing **6% on the 10-year Treasury yield** as the next potential pain threshold. 

Why 6%?

Because at that level, borrowing costs could start to **rattle financial markets and Corporate America** in ways that force a reckoning. 

Here's what happens when the 10-year hits 6%:

- **Mortgage rates could approach 8%**, effectively shutting down the housing market for anyone who doesn't have cash.

- **Corporate bond issuance could freeze**, as companies decide that borrowing is too expensive.

- **Equity valuations could compress**, because higher discount rates make future earnings less valuable today.

- **The Fed could face pressure to intervene**, either by slowing its tightening or by taking emergency measures.

We're not at 6% yet. But the speed of the move — the 10-year has risen **0.70 percentage points since June** and **1.25 percentage points since early March** — has investors nervous. 

**Gennadiy Goldberg, head of U.S. rates strategy at TD Securities**, broke down the drivers: **"The vast majority of the move higher in yields since March has been driven by rising Fed expectations, with the remainder driven by a combination of rising growth expectations and higher oil prices."** 

That's a lot of forces pushing in the same direction. And none of them are showing signs of reversing.

---

## Frequently Asked Questions

**Q: What exactly happened to Treasury yields this week?**

A: The 30-year Treasury yield hit **5.48%**, its highest since 2004. The 10-year touched **5.225%**, its highest since July 2007. The 2-year climbed to **4.90%**. Yields rose for a sixth consecutive week, marking the longest weekly losing streak for the 10-year since November 2024. 

**Q: Why are yields rising so fast?**

A: Three main factors: (1) The Fed raised rates in September and signaled more hikes to come. (2) Oil prices surged above $100 on Middle East tensions, feeding inflation fears. (3) Economic data — especially the S&P Global PMI — showed the economy is booming, not slowing, which supports higher rates. 

**Q: What does this mean for mortgage rates?**

A: Mortgage rates follow the 10-year Treasury yield. With the 10-year at 5.22%, the 30-year fixed mortgage rate is around **7%** — near its highest in two years. Further increases in Treasury yields could push mortgage rates toward 8%. 

**Q: Should I sell my bonds?**

A: This article is not financial advice. But generally speaking, selling bonds after a selloff locks in losses. If you hold individual bonds to maturity, you'll get your principal back. If you own bond funds, the value may recover if yields eventually fall. Consult a financial advisor about your specific situation.

**Q: Is this a bond market crash?**

A: The selloff is significant — the 30-year yield hitting a 22-year high is a major move. But "crash" implies panic and disorder. So far, the market has been orderly. Investors are absorbing higher yields because the underlying economy is strong and corporate profits are booming. 

**Q: What is the Fed doing about this?**

A: The Fed raised rates in September and signaled more hikes ahead. Fed Chair Warsh has emphasized that the economy is strong enough to handle tighter policy. However, if yields rise too far too fast, the Fed could face pressure to adjust its stance. 

**Q: Why is the 30-year yield hitting a 22-year high significant?**

A: The 30-year yield reflects investors' willingness to lend money to the government for three decades. When it rises this high, it signals that investors are demanding more compensation for long-term risks — including inflation, government debt, and fiscal uncertainty. It also directly affects 30-year mortgage rates. 

**Q: How does this affect the stock market?**

A: Rising yields pressure stock valuations by increasing the discount rate applied to future earnings. Growth stocks — especially tech — are most sensitive. However, stocks have held up relatively well this week, suggesting investors see the yield rise as driven by economic strength rather than crisis. 

**Q: Is this happening globally?**

A: Yes. Japan's 10-year yield hit its highest since 1996. Germany's 10-year Bund hit its highest in 17 years. The U.K. and Australia have also seen yields rise. This is a global repricing of bonds, driven by synchronized central bank tightening and energy-driven inflation. 

**Q: What should I watch next week?**

A: Key indicators include: (1) oil prices, (2) any new inflation data, (3) Fed speakers for clues about October, and (4) whether the 10-year breaks decisively above 5.25% or retreats. The 6% level is the big psychological threshold to watch. 

---

## Conclusion: A Week That Changed the Math

Here's what I keep coming back to when I think about Patricia, the retired teacher.

She called her broker, confused and worried. He tried to explain. But the truth is, the explanation doesn't make her feel better.

The world of finance is complicated. Yields, prices, basis points, dot plots — it's a language most Americans don't speak. But the consequences are felt in every household.

When Treasury yields rise, **mortgages get more expensive**. **Car loans get more expensive**. **Credit card rates go up**. **Businesses pay more to borrow**. **Retirement portfolios lose value**.

This week, the 30-year Treasury yield hit a **22-year high**. The 10-year hit its highest since **2007**. And the forces driving those moves — Fed tightening, surging oil, a booming economy — show no signs of reversing.

For bond investors, the pain may continue. For homebuyers, the dream is getting more expensive. For retirees, the nest egg is shrinking.

But for savers with cash, there's opportunity. For investors with patience, higher yields mean better long-term returns. And for the economy, the fact that all of this is happening without panic suggests something important: **the underlying foundation is strong**.

That doesn't make the pain less real. But it does mean this isn't 2008. It's not a crisis. It's a repricing.

The question is: how far will it go?

The 10-year Treasury yield is the most important number in finance. And right now, it's telling a story of an economy that refuses to slow down, inflation that refuses to die, and a Fed that refuses to blink.

Patricia doesn't need to understand all of that. She just needs to know whether her retirement is safe.

The honest answer is: it depends. On how much she owns in long-term bonds. On how long she can wait. On whether yields eventually come down.

That's not the answer anyone wants. But it's the truth. And in a week like this, the truth is the only thing that matters.

---

## Disclaimer

**This article is for informational and educational purposes only. It does not constitute investment, financial, or trading advice. The author has no positions in any securities mentioned. Information presented here is based on publicly available sources and reported figures as of the publication date. Market conditions change rapidly, and bond prices and yields are subject to significant volatility. The anecdotal accounts presented are illustrative and do not represent specific individuals. Past performance does not guarantee future results. Investing involves risk, including the potential loss of principal. Always consult with a qualified financial advisor before making any investment decisions.**